PROCARDIA Drug Patent Profile

Which patents cover Procardia, and what generic alternatives are available?

Procardia is a drug marketed by Pfizer and is included in two NDAs.

The generic ingredient in PROCARDIA is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the nifedipine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Procardia

A generic version of PROCARDIA was approved as nifedipine by ACTAVIS ELIZABETH on January 8^th, 1991.

Summary for PROCARDIA

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	165
Clinical Trials:	11
Patent Applications:	3,782
Drug Prices:	Drug price information for PROCARDIA
What excipients (inactive ingredients) are in PROCARDIA?	PROCARDIA excipients list
DailyMed Link:	PROCARDIA at DailyMed

See drug prices for PROCARDIA

Recent Clinical Trials for PROCARDIA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical College of Wisconsin	N/A
Icahn School of Medicine at Mount Sinai	Phase 4
High Risk Obstetrical Consultants	Early Phase 1

See all PROCARDIA clinical trials

US Patents and Regulatory Information for PROCARDIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	PROCARDIA	nifedipine	CAPSULE;ORAL	018482-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Pfizer	PROCARDIA XL	nifedipine	TABLET, EXTENDED RELEASE;ORAL	019684-002	Sep 6, 1989	AB2	RX	Yes	No
Pfizer	PROCARDIA	nifedipine	CAPSULE;ORAL	018482-002	Jul 24, 1986		DISCN	Yes	No
Pfizer	PROCARDIA XL	nifedipine	TABLET, EXTENDED RELEASE;ORAL	019684-001	Sep 6, 1989	AB2	RX	Yes	No
Pfizer	PROCARDIA XL	nifedipine	TABLET, EXTENDED RELEASE;ORAL	019684-003	Sep 6, 1989	AB2	RX	Yes	Yes

Expired US Patents for PROCARDIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	PROCARDIA	nifedipine	CAPSULE;ORAL	018482-001	Approved Prior to Jan 1, 1982
Pfizer	PROCARDIA	nifedipine	CAPSULE;ORAL	018482-002	Jul 24, 1986
Pfizer	PROCARDIA	nifedipine	CAPSULE;ORAL	018482-002	Jul 24, 1986
Pfizer	PROCARDIA	nifedipine	CAPSULE;ORAL	018482-001	Approved Prior to Jan 1, 1982

International Patents for PROCARDIA

See the table below for patents covering PROCARDIA around the world.

Country	Patent Number	Title	Estimated Expiration
Czechoslovakia	199202	METHOD OF PRODUCING GELATINE CAPSULES TO BE BITTEN UP
Canada	981582	CORONARY DILATOR IN A PHARMACEUTICAL DOSAGE UNIT FORM
Denmark	130628
Bulgaria	27728	METOD ZA POLUCHAVANE NA KORONARNO SREDSTVO (METHOD FOR OBTAINING OF CORONAL MEANS)
Kenya	2756	CAPSULES COMPRISING A CORONARY-DILATING COMPOUND

PROCARDIA Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Nifedipine (Procardia)

Introduction

Nifedipine, commonly known by its brand name Procardia, is a calcium channel blocker used to treat hypertension and angina. The market for Nifedipine is influenced by several key factors, including the prevalence of cardiovascular diseases, technological advancements, and changes in healthcare infrastructure.

Market Size and Growth

The global Nifedipine market was valued at $824.3 million in 2023 and is projected to grow to $1,661.5 million by 2032, with a Compound Annual Growth Rate (CAGR) of 8.1% during this period[1][4].

Key Drivers of the Market

Increasing Prevalence of Cardiovascular Diseases

The rising global incidence of cardiovascular diseases such as hypertension and angina is a primary driver for the Nifedipine market. As the population ages and lifestyle factors contribute to an increase in these conditions, the demand for medications like Nifedipine is expected to rise[1][4].

Technological Advancements in Drug Formulations

Ongoing research and development have led to technological advancements in Nifedipine formulations. Improved drug delivery systems and innovative formulations enhance efficacy, reduce side effects, and offer convenient dosage options, which can increase patient compliance and market share[1][4].

Growing Aging Population

The demographic shift towards an aging population is significant. Elderly individuals are more prone to cardiovascular issues, which increases the demand for medications like Nifedipine. This demographic trend is expected to continue driving market growth[1].

Expansion of Healthcare Infrastructure in Emerging Markets

The growth and improvement of healthcare infrastructure in emerging markets contribute to increased access to medications. As these regions focus on better healthcare services, the demand for cardiovascular drugs, including Nifedipine, experiences a positive impact[1].

Market Dynamics

Patient Adherence and Compliance

Patient adherence to prescribed medications is crucial for the Nifedipine market. Poor adherence can lead to treatment failure or complications, impacting the overall market. Strategies to improve patient education and adherence are essential for ensuring consistent usage of Nifedipine[4].

Generic Competition and Pricing

Nifedipine has been available in generic forms, which affects the pricing and competition within the market. Generic versions often result in lower prices, making the drug more accessible to a larger population. This competition influences the pricing strategies of existing market players[4].

Regulatory Environment

Changes in regulatory policies and approvals can affect the market dynamics of Nifedipine. Updates in safety standards or new indications approved by regulatory bodies can impact market growth and competitiveness[4].

Telehealth and Digital Health Integration

The increasing acceptance of telehealth services presents an opportunity for the Nifedipine market. Integrating digital health solutions for remote patient monitoring and consultations enhances accessibility, especially in regions with limited healthcare infrastructure[1].

Financial Trajectory

Revenue Projections

The global Nifedipine market is expected to expand significantly, reaching $1,661.5 million by 2032. This growth is driven by the increasing prevalence of cardiovascular diseases, technological advancements, and the expansion of healthcare infrastructure in emerging markets[1][4].

Cost Savings and Economic Impact

Studies have shown that switching from one calcium channel blocker to another, such as from Procardia XL to Adalat CC, can result in significant cost savings. For example, a study using Medicaid claims data indicated potential savings of more than $2.5 million annually for Medicaid patients in Pennsylvania by switching to the more cost-effective option[3].

Competitive Landscape

The competitive landscape of the Nifedipine market includes various pharmaceutical companies, some of which have expanded their operations through mergers and acquisitions. For instance, companies like Valeant (now part of Bausch Health) have focused on growth through strategic acquisitions and the expansion of their product lines in emerging markets[2].

Regional Market Analysis

North America and Europe

These regions have well-established healthcare systems and a high prevalence of cardiovascular diseases, contributing to a significant market share for Nifedipine. However, the market is also influenced by generic competition and regulatory environments in these regions[1].

Asia-Pacific

The Asia-Pacific region is witnessing significant growth due to the expansion of healthcare access in rural areas and the adoption of telemedicine. Governments are investing in healthcare infrastructure development, facilitating increased availability of Nifedipine[1].

Latin America, Middle East, and Africa (LAMEA)

In LAMEA, there is a shift towards value-based care models, focusing on achieving better health outcomes and efficient use of resources. This trend influences the adoption of medications like Nifedipine as part of comprehensive cardiovascular care strategies[1].

Key Takeaways

• The global Nifedipine market is projected to grow significantly, driven by the increasing prevalence of cardiovascular diseases and technological advancements.
• Patient adherence and compliance are crucial for the market's success.
• Generic competition and regulatory changes play significant roles in market dynamics.
• Emerging markets and the integration of telehealth services are key growth drivers.
• The market is expected to reach $1,661.5 million by 2032, with a CAGR of 8.1%.

FAQs

What is the projected market size of Nifedipine by 2032?

The global Nifedipine market is expected to reach $1,661.5 million by 2032[1][4].

What are the primary drivers of the Nifedipine market?

The primary drivers include the increasing prevalence of cardiovascular diseases, technological advancements in drug formulations, and the growing aging population[1][4].

How does generic competition affect the Nifedipine market?

Generic competition affects pricing and makes the drug more accessible to a larger population, influencing the pricing strategies of existing market players[4].

What role does telehealth play in the Nifedipine market?

Telehealth services enhance accessibility, especially in regions with limited healthcare infrastructure, by integrating digital health solutions for remote patient monitoring and consultations[1].

Which regions are expected to see significant growth in the Nifedipine market?

The Asia-Pacific region and emerging markets in LAMEA are expected to see significant growth due to the expansion of healthcare infrastructure and the adoption of telemedicine[1].

Sources

1. Custom Market Insights - Global Nifedipine Market Size, Trends, Share, Forecast 2032
2. Annual Reports - Valeant Annual Report 2010
3. PubMed - The costs and effects of switching calcium channel blockers
4. Custom Market Insights - Global Nifedipine Market Size Reach $1,661.5 Million 2032
5. GlobeNewswire - Nifedipine Medication Market to Hit US$ 1936.9 Million, Globally, by ...